Details of the Drug Reposition

General Information of This Drug (ID: DML4ZOT)

Drug Name	Lidocaine DML4ZOT
Synonyms	Alphacaine; Anestacon; Cappicaine; Cuivasil; Dalcaine; Dentipatch; DermaFlex; Dilocaine; Duncaine; EMBOLEX; Esracaine; Gravocain; Isicaina; Isicaine; Jetocaine; LIDOPEN; LQZ; Lanabiotic; Leostesin; Lidocaina; Lidocainum; Lidocaton; Lidoderm; Lignocaine; Lignocainum; Lingocaine; Maricaine; Octocaine; Remicaine; Rucaina; Solcain; Xilina; Xilocaina; Xllina; Xycaine; Xylestesin; Xylesthesin; Xylocain; Xylocaine; Xylocard; Xylocitin; Xylotox; Zingo; After Burn Double Strength Gel; After Burn Double Strength Spray; After Burn Gel; After Burn Spray; Anestacon Jelly; Cito optadren; Emla Cream; Lidocaine Carbonate; Lidocaine Hydrocarbonate; Lidocaine Monohydrochloride; Norwood Sunburn Spray; Rocephin Kit; Solarcaine aloe extraburn relief cream; Xilocaina [Italian]; Xylocaine Dental Ointment; Xylocaine Endotracheal; Xylocaine Test Dose; Xylocaine Viscous; CDS1_000283; L1026_SIGMA; Xylocaine CO2; Dentipatch (TN); ELA-Max; L-Caine; Lida-Mantle; Lidocaina [INN-Spanish]; Lidocaine (VAN); Lidocainum [INN-Latin]; Lidoject-1; Lidoject-2; Octocaine-100; Octocaine-50; Xylocaine (TN); Xylocaine 5% Spinal; Xylocaine-Mpf; Xylocaine-Mpf with Glucose; Xyloneural (free base); Zilactin-L; Lidocaine [USAN:INN:JAN]; Diethylaminoaceto-2,6-xylidide; Lidocaine (JP15/USP/INN); Alfa-Dietilamino-2,6-dimetilacetanilide; Alfa-Dietilamino-2,6-dimetilacetanilide [Italian]; Alpha-Diethylamino-2,6-dimethylacetanilide; Alpha-Diethylaminoaceto-2,6-xylidide; LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE); Omega-Diethylamino-2,6-dimethylacetanilide; Alpha-(Diethylamino)-2,6-acetoxylidide; N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide; N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide; 2-(Diethylamino)-2',6'-acetoxylidide; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; 2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide; 2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
Therapeutic Class	Anesthetics
Drug Type	Small molecular drug
Structure
Structure	3D MOL	2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

9 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Pthirus pubis infestation	DIS7TJWV	N.A.	Approved	[1]
Carpal tunnel syndrome	DISHQ3BE	N.A.	Approved	[1]
Postherpetic neuralgia	DISCQ39I	1E91.5	Approved	[1]
Pediculus capitis infestation	DISLZYDI	1G00.0	Approved	[1]
Anaesthesia	DIS5D4R1	9A78.6	Approved	[2]
Long QT syndrome	DISMKWS3	BC65.0	Approved	[1]
Periodontitis	DISI9JOI	DA0C	Approved	[1]
Interstitial cystitis	DIS7CAJA	GC00.3	Approved	[1]
Pain	DIS4RWOW	MG30-MG3Z	Approved	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Indications(s)

1 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Dysmenorrhea	DISMYBW9	GA34.3	Phase 2	[3]
------------------------------------------------------------------------------------

1 Discontinued in Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Hemorrhoids	DISQ5G6G	DB60	Discontinued in Phase 3	[4]
------------------------------------------------------------------------------------

3 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Scabies	DIST42FH	N.A.	Discontinued in Phase 2	[5]
Urethritis	DISSWPSQ	N.A.	Discontinued in Phase 2	[6]
Overactive bladder	DISQR5TD	GC50.0	Discontinued in Phase 2	[7]
------------------------------------------------------------------------------------

4 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Neuralgia	DISWO58J	N.A.	Investigative	[1]
Pruritus	DISVH62W	EC90	Investigative	[1]
Premature ejaculation	DISU51JD	HA03.0Z	Investigative	[1]
Chronic pain	DISXRS8Y	MG30	Investigative	[1]
------------------------------------------------------------------------------------

References

1	Lidocaine FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2623).
3	ClinicalTrials.gov (NCT00651313) Efficacy and Safety Study of Lidocaine Vaginal Gel for Recurrent Dysmenorrhea (Painful Periods). U.S. National Institutes of Health.
4	S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone Surgery
5	Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer
6	Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes
7	Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma